Yarrow Bioscience files 8-K disclosing acquisition, management changes, and equity issuance

Yarrow Bioscience has filed an 8-K reporting a material definitive agreement, an asset acquisition, and a change in corporate control. The filing also details executive leadership departures and the issuance of unregistered equity securities, signaling a significant restructuring of the firm's operations and governance.